STERIS plc

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

Reasons to Retain STE Stock in Your Portfolio for Now

AI-generated analysis

📈 STERIS plc's STE Healthcare segment is experiencing strong market adoption of its infection prevention consumables and capital equipment.

💰 The Applied Sterilization Technologies (AST) segment is benefiting from robust service revenues, which is encouraging growth.

⚠️ Macroeconomic volatilities and unfavorable foreign exchange rates raise concerns for the company's reported results.

📉 Over the past year, STE shares lost 9.6% compared with the industry's 4.2% decline and the S&P 500's 32.5% rise.

💵 The company has a market capitalization of $21.18 billion and an earnings yield of 5.1%, well above the industry's negative 2.2%.

📊 STE delivered an average earnings surprise of 0.9% for the trailing four quarters.

🏥 Healthcare revenues increased 7% to $1.14 billion in the fiscal fourth quarter, with service up 9% and consumables up 7%.

🔧 Capital equipment backlog ended just under $400 million, with orders up 2% in the fiscal fourth quarter.

🌍 The AST segment operates a worldwide network of over 50 contract sterilization and laboratory facilities.

📈 For fiscal 2026, AST revenues are projected to increase 10%, aligning with the company's longer-term expectations.

💸 In the fourth quarter, capital equipment revenues for AST declined 62% while services revenue grew 10%.

🌐 Foreign exchange volatility can impact reported results and competitiveness due to a meaningful portion of revenues generated outside the U.S.

📉 Global macro pressure and healthcare cost-containment efforts continue to weigh on spending and pricing in the industry.

🛑 Tariffs implemented by the new U.S. government are expected to add approximately $46 million in costs for 2026, trimming margins by 80 basis points.

📉 Selling, general and administrative expenses increased 5.4%, while research and development expenses rose 4%.

🔮 The Zacks Consensus Estimate for fiscal 2027 earnings per share indicates a 0.4% increase to $11.09.

📈 The consensus mark for fiscal 2027 revenues is pegged at $6.37 billion, suggesting 7.4% growth from the fiscal 2026 reported number.

🔍 Other better-ranked stocks in the broader medical space include Globus Medical (GMED), Alcon (ALC), and Phibro Animal Health (PAHC).

🚀 Globus Medical has a Zacks Rank #1 (Strong Buy) with shares rallying 28.1% against the industry's decline over the past year.

💰 Alcon carries a Zacks Rank #2 (Buy) with an earnings yield of 5.2% against the industry's negative 2.2%.

🐾 Phibro Animal Health has an estimated long-term earnings growth rate of 21.5% compared with the industry's 12.1%.

Bullish Signals
  • STERIS plc's Healthcare segment delivered strong revenue growth, with full-year revenues rising to $4.21 billion and service revenues increasing by 12%.
  • The Applied Sterilization Technologies (AST) segment reached a significant milestone by surpassing $500 million in operating profit while generating over $1 billion in revenues.
  • For fiscal 2026, AST revenues are projected to increase by 10%, aligning with the company's longer-term expectations for sustained growth.
  • STERIS has an earnings yield of 5.1%, which is well above the industry's negative 2.2% yield, indicating strong profitability relative to peers.
  • The company delivered an average earnings surprise of 0.9% over the trailing four quarters, demonstrating consistent performance against analyst estimates.
  • Capital equipment backlog ended just under $400 million with orders up 2% in the fiscal fourth quarter, signaling robust future demand.
  • Despite macroeconomic headwinds, the company expects a slightly favorable foreign exchange impact for its international operations.
Risk Factors
  • STERIS shares have lost 9.6% over the past year, significantly underperforming the industry's 4.2% decline and the S&P 500's 32.5% rise.
  • The company faces meaningful foreign exchange volatility risks due to a large portion of revenues and costs being generated outside the United States.
  • Global macroeconomic pressures and healthcare cost-containment efforts are weighing on spending and pricing power for the company.
  • Implementation of tariffs by the new U.S. government is expected to add approximately $46 million in incremental costs in 2026, trimming margins by 80 basis points.
  • Operating expenses have escalated significantly, with selling, general, and administrative expenses increasing 5.4% and research and development expenses rising 4%.
  • These combined cost pressures led to an adjusted operating margin contraction of 61 basis points.
Full Analysis
STERIS plc's STE Healthcare segment is demonstrating strong market adoption with infection prevention consumables and capital equipment driving growth. In the fiscal fourth quarter, Healthcare revenues increased 7% to $1.14 billion, fueled by a 9% rise in services, 7% growth in consumables, and 6% growth in capital equipment. For the full year, Healthcare revenues reached $4.21 billion with service growing 12% and capital equipment up 6%. The Applied Sterilization Technologies (AST) segment is also gaining traction, particularly in ethylene oxide sterilization for biopharmaceutical manufacturers. Fiscal 2026 AST revenues increased 10% to surpass $500 million in operating profit, with fourth-quarter revenues rising 6% year over year to $289.2 million driven by an 11% increase in services revenue. Despite these operational strengths, the company faces headwinds from macroeconomic volatility and unfavorable foreign exchange rates which impact reported results and competitiveness. Additionally, STERIS is dealing with increasing costs due to new U.S. government tariffs, with incremental tariff costs of approximately $46 million in 2026 expected to trim margins by 80 basis points. These factors have led to an escalation in operating expenses, including a 5.4% increase in selling, general and administrative expenses and a 4% rise in research and development expenses, resulting in an adjusted operating margin contraction of 61 basis points. Looking ahead, the Zacks Consensus Estimate for fiscal 2027 earnings per share indicates a 0.4% increase to $11.09, with consensus revenues pegged at $6.37 billion suggesting 7.4% growth from fiscal 2026 reported numbers. The company has a market capitalization of $21.18 billion and an earnings yield of 5.1%, which is well above the industry's negative 2.2% yield. STE shares have lost 9.6% over the past year compared to the industry's 4.2% decline, while the S&P 500 composite has risen 32.5% during the same period. The company holds a Zacks Rank #3 (Hold) rating.